MX2021001857A - Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. - Google Patents
Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.Info
- Publication number
- MX2021001857A MX2021001857A MX2021001857A MX2021001857A MX2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A MX 2021001857 A MX2021001857 A MX 2021001857A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- individual
- treatment
- methods
- tissue sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Se proporciona en la presente descripción, entre otros, métodos de diagnóstico predictivo, farmacodinámicos y terapéuticos para el tratamiento del cáncer de mama. En modalidades, los métodos y composiciones se basan, al menos en parte, en el descubrimiento de que la puntuación inducida por estradiol (E2) o la puntuación de la actividad de la vía del receptor de estrógeno (ER) determinada a partir de una muestra (por ejemplo, una muestra de tejido, por ejemplo, una muestra de tejido tumoral, por ejemplo, una muestra de tejido tumoral FFPE, una FF, de archivo, una fresca o una congelada) de un individuo se puede usar en métodos para determinar si el individuo que tiene cáncer de mama es probable que responda a un tratamiento que incluye una terapia endocrina, seleccionar una terapia para un individuo que tiene cáncer de mama; tratar a un individuo que tiene cáncer de mama; y monitorear la eficacia terapéutica de una terapia endocrina, así como también kits relacionados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862719545P | 2018-08-17 | 2018-08-17 | |
PCT/US2019/046814 WO2020037203A2 (en) | 2018-08-17 | 2019-08-16 | Diagnostic and therapeutic methods for the treatment of breast cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021001857A true MX2021001857A (es) | 2021-10-13 |
Family
ID=67809706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021001857A MX2021001857A (es) | 2018-08-17 | 2019-08-16 | Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11081236B2 (es) |
EP (1) | EP3837548A2 (es) |
JP (1) | JP2021533787A (es) |
KR (1) | KR20210046031A (es) |
CN (1) | CN113490850A (es) |
AU (1) | AU2019321588A1 (es) |
CA (1) | CA3109090A1 (es) |
IL (1) | IL280707A (es) |
MX (1) | MX2021001857A (es) |
TW (1) | TW202022124A (es) |
WO (1) | WO2020037203A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210046031A (ko) | 2018-08-17 | 2021-04-27 | 에프. 호프만-라 로슈 아게 | 유방암 치료를 위한 진단 및 치료 방법들 |
WO2021178846A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
US11918561B2 (en) | 2020-05-12 | 2024-03-05 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor |
CN111893112A (zh) * | 2020-08-12 | 2020-11-06 | 上海尤里卡信息科技有限公司 | 胃癌肿瘤标志物及其应用 |
CN114105977B (zh) * | 2020-08-28 | 2023-09-01 | 先声再明医药有限公司 | 雌激素受体调节剂化合物及其用途 |
US20240002950A1 (en) * | 2020-11-23 | 2024-01-04 | Sanofi | Panel of ER Regulated Genes for Use in Monitoring Endocrine Therapy in Breast Cancer |
WO2022140744A1 (en) | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
CN116744920A (zh) * | 2021-02-08 | 2023-09-12 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
EP4294395A1 (en) | 2021-02-16 | 2023-12-27 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 |
JP2024506348A (ja) | 2021-02-16 | 2024-02-13 | ジェネンテック, インコーポレイテッド | Gdc-9545とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療 |
TW202237099A (zh) | 2021-02-16 | 2022-10-01 | 美商建南德克公司 | 使用包含gdc-9545及帕他色替之組合療法治療乳癌 |
CA3217423A1 (en) | 2021-06-16 | 2022-12-22 | Jeffrey M. Schkeryantz | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
CN117813288A (zh) * | 2021-07-15 | 2024-04-02 | 西藏海思科制药有限公司 | 芳氨基衍生物雌激素受体调节剂及其用途 |
WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
WO2023198907A1 (en) * | 2022-04-15 | 2023-10-19 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof |
WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
WO2024015506A1 (en) * | 2022-07-14 | 2024-01-18 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
WO2024076626A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
US6638727B1 (en) * | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
CN1526025A (zh) * | 2001-05-16 | 2004-09-01 | ��˹��ŵ�� | 作为预后和治疗靶标的乳腺癌中表达的基因 |
CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
BRPI0414553A (pt) * | 2003-09-19 | 2006-11-07 | Arcturus Bioscience Inc | previsão do resultado de tratamento contra o cáncer de mama |
CA2698569A1 (en) * | 2007-09-06 | 2009-09-03 | Mark G. Erlander | Tumor grading and cancer prognosis |
CN102939287B (zh) | 2010-06-10 | 2016-01-27 | 塞拉根制药公司 | 雌激素受体调节剂及其用途 |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
CN104302286A (zh) * | 2012-03-27 | 2015-01-21 | 英丘伦有限责任公司 | 用于治疗乳腺癌的curaxin和用于鉴别可能响应的患者的方法 |
US20150284357A1 (en) | 2012-10-24 | 2015-10-08 | Gregory R. Thatcher | Compositions and methods for treating estrogen-related medical disorders |
CA2928173C (en) | 2012-10-24 | 2021-10-19 | The Board Of Trustees Of The University Of Illinois | Compositions comprising benzothiophene derivatives and use thereof for treatment of estrogen-related medical disorders |
KR102279844B1 (ko) | 2012-12-26 | 2021-07-21 | 코닌클리케 필립스 엔.브이. | 타깃 유전자 발현의 선형 조합(들)을 사용한 세포 시그널링 경로 활성의 평가 |
US9586952B2 (en) | 2013-03-14 | 2017-03-07 | Genentech, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
EP3044335B1 (en) | 2013-09-11 | 2020-09-09 | Bio Theranostics, Inc. | Predicting breast cancer recurrence |
EP3210144B1 (en) * | 2014-10-24 | 2020-10-21 | Koninklijke Philips N.V. | Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities |
CN108349952A (zh) | 2015-11-09 | 2018-07-31 | 豪夫迈·罗氏有限公司 | 四氢萘雌激素受体调节剂及其用途 |
BR112018015419B1 (pt) | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
MX2018009908A (es) | 2016-02-15 | 2018-09-07 | Sanofi Sa | Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos. |
SG11201808363TA (en) | 2016-03-25 | 2018-10-30 | Luoxin Biotechnology Shanghai Co Ltd | Substituted-indole compounds as estrogen receptor degrading agent |
CN109843882A (zh) | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
JP7018026B2 (ja) | 2016-06-16 | 2022-02-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
US10131663B2 (en) | 2016-10-24 | 2018-11-20 | Astrazeneca Ab | Chemical compounds |
US10774081B2 (en) | 2016-10-28 | 2020-09-15 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Indolo substituted piperidine compound as estrogen receptor down-regulator |
AU2017362460B2 (en) | 2016-11-17 | 2021-07-22 | Sanofi | Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
KR20210046031A (ko) | 2018-08-17 | 2021-04-27 | 에프. 호프만-라 로슈 아게 | 유방암 치료를 위한 진단 및 치료 방법들 |
-
2019
- 2019-08-16 KR KR1020217007867A patent/KR20210046031A/ko not_active Application Discontinuation
- 2019-08-16 TW TW108129347A patent/TW202022124A/zh unknown
- 2019-08-16 MX MX2021001857A patent/MX2021001857A/es unknown
- 2019-08-16 JP JP2021507927A patent/JP2021533787A/ja active Pending
- 2019-08-16 AU AU2019321588A patent/AU2019321588A1/en active Pending
- 2019-08-16 CN CN201980067809.7A patent/CN113490850A/zh active Pending
- 2019-08-16 EP EP19762044.6A patent/EP3837548A2/en active Pending
- 2019-08-16 WO PCT/US2019/046814 patent/WO2020037203A2/en unknown
- 2019-08-16 CA CA3109090A patent/CA3109090A1/en active Pending
- 2019-08-16 US US16/542,817 patent/US11081236B2/en active Active
-
2021
- 2021-02-08 IL IL280707A patent/IL280707A/en unknown
- 2021-06-25 US US17/359,186 patent/US11676731B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20200082944A1 (en) | 2020-03-12 |
US11676731B2 (en) | 2023-06-13 |
US11081236B2 (en) | 2021-08-03 |
CN113490850A (zh) | 2021-10-08 |
IL280707A (en) | 2021-03-25 |
TW202022124A (zh) | 2020-06-16 |
JP2021533787A (ja) | 2021-12-09 |
AU2019321588A1 (en) | 2021-03-04 |
EP3837548A2 (en) | 2021-06-23 |
KR20210046031A (ko) | 2021-04-27 |
WO2020037203A2 (en) | 2020-02-20 |
CA3109090A1 (en) | 2020-02-20 |
US20220044819A1 (en) | 2022-02-10 |
WO2020037203A3 (en) | 2020-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021001857A (es) | Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. | |
Wiegner et al. | Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial | |
MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
MXPA05009044A (es) | Metodos para utilizar celulas derivadas de tejido adiposo en el tratamiento de condiciones cardiovasculares. | |
BR112022020817A2 (pt) | Inibidores de kif18a para tratamento de doenças neoplásicas | |
WO2006014159A3 (en) | Methods of using regenerative cells in the treatment of musculoskeletal disorders | |
WO2017100663A8 (en) | Improved methods for treating her2-positive breast cancer | |
MX2021003214A (es) | Metodos terapeuticos y de diagnostico para el cancer de vejiga. | |
Johnston et al. | The optimal duration of adjuvant endocrine therapy for early stage breast cancer—with what drugs and for how long? | |
Zhang et al. | The use of unilateral or bilateral external oblique myocutaneous flap in the reconstruction of lower abdominal wall or groin defects after malignant tumor resection | |
MX2021009247A (es) | Metodos, sistemas y kits para tratar enfermedades inflamatorias que se dirigen a il18r1. | |
Davidson | PG 11.01 Endocrine therapy for premenopausal women: type and duration | |
Koh et al. | Comparing a volume based template approach and ultrasound guided freehand approach in multicatheter interstitial accelerated partial breast irradiation | |
MX2021005189A (es) | Uso de tivozanib para tratar sujetos con cancer refractario. | |
Milecki et al. | Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients? | |
Karimkhani et al. | Extraosseous extension of multiple myeloma: a cutaneous herald to systemic disease | |
DK1778834T3 (da) | Fremgangsmåder til anvendelse af regenerative celler i behandlingen af renale sygdomme og lidelser | |
Deantonio et al. | Hypofractionated volumetric modulated arc therapy (VMAT) in the treatment of advanced oesophageal cancer | |
Singhal et al. | Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant) | |
Parks et al. | THE ROLE OF THE ANDROGEN RECEPTOR IN PRIMARY BREAST CANCER IN OLDER WOMEN | |
Dieleman et al. | OP003/# 32 Preferences and experiences regarding the use of the self-sampling device in the hrHPV screening for cervical cancer | |
Bogani et al. | OP004/# 35 BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer | |
Jongen | The search for new therapeutic targets in breast cancer: human epidermal growth factor receptor 2 mutations and the androgen receptor | |
NilujaThiruthaneeswaran et al. | Cancer in the Very Elderly and Management | |
Alsanabani et al. | Reliability of Oncoplastic Breast Conserving Surgery for Management of Early Breast Cancer in Yemeni Patients |